



23 February 2021

Sydney, Australia

Investor Presentation to Finance News Network CEO Showcase

Sydney, 23 February 2021: Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be used by Nyrada CEO, James Bonnar at the Finance News Network CEO Showcase webinar to be held today, from 12.30pm (AEDT).

Mr Bonnar will provide an update on the progress of the Company's lead drug development programs.

The webinar is free to attend. To register for the event, please use the following link: <https://www.finnewsnetwork.com.au/page/investor-events>

A replay of the webinar will also be available to view after the event via the Company's website at: <https://www.nyrada.com/site/investors/presentations>

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

**Media Enquiries:**

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.



INVESTOR PRESENTATION

Finance News Network CEO Showcase

James Bonnar
Nyrada CEO

23 February 2021



Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.



Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Vision

We can improve lives and offer hope through innovation

-  Deliver a cost-competitive and convenient cholesterol-lowering treatment to help achieve target safe cholesterol level
Reduce risk of cardiovascular disease (heart attack and stroke)
-  Deliver the first-ever treatment to prevent brain damage following stroke and head trauma (falls, motor vehicle accidents)
Improve survivability, reduce disability

Mission

Advance our drug candidates towards value inflection and commercialise early

Business Strategy

Drug discovery
and early-stage
developer

Cholesterol-Lowering drug

Oral *PCSK9 inhibitor* to be used alone as a monotherapy, or in combination with a statin
- Out-license following Phase I study

Brain Injury drug

Intravenous and intranasal drug to help people who sustain a traumatic brain injury (TBI) or suffer a stroke
- Out-license following Phase II study

Innovative Treatments

Best-in-Class / First-Line

Clinical Need

Strong Patent Protection

Market Potential


Commercialise Early

Problem – High LDL Cholesterol

High LDL Cholesterol leading cause of cardiovascular disease

Cardiovascular disease responsible for 1-in-4 deaths¹

62.6 million US adults with elevated LDL-C²



1. Centers for Disease Control and Prevention, Heart Disease Facts: Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association.
2. Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016


Statin Drugs



Low cost



Suboptimal efficacy



27.4 million
US adults with elevated
LDL-C are taking a statin

Current PCSK9 Inhibitors



Binds to PCSK9 protein

Blocks action of PCSK9
on cholesterol receptor



Effective, combined with a statin



Expensive US\$5,800 per year
Inconvenient (2-4 weekly injections)

Statin + current PCSK9 inhibitor = expensive and inconvenient

What is Unique?


Oral PCSK9
treatment

Convenient
for patient


Cost-
effective

Small molecule PCSK9 inhibitor
overcomes longstanding challenge of
oral treatment

Can be combined with statin
to deliver a first ever
single pill PCSK9/statin treatment



Cholesterol Reduction with NYX-PCSK9i



% difference in plasma total cholesterol versus vehicle control (*p*-value)

Time (days)	7	14	21	28
30 mg/kg NYX-PCSK9i	-14% (0.05)	-23% (0.015)	-32% (0.002)	-36% (<0.001)
50 mg/kg NYX-PCSK9i	-16% (0.05)	-40% (<0.001)	-50% (<0.001)	-57% (<0.001)
Exploratory 10 mg/kg	0% (0.95)	-4% (0.505)	-	-
Exploratory 75 mg/kg	-	-	-36% (<0.001)	-48% (<0.001)

Brain Injury Problem


Each year in the US:

- 2.8 million people sustain a traumatic brain injury (TBI)
- 800,000 suffer a stroke


Neurology / physical rehabilitation are the only existing therapies

- One drug class for stroke (Suitable for less than 15% of patients)
- No treatment exists for TBI


- High mortality
- Severe life-long disability
- High ongoing healthcare cost



Minutes



Hours




Days

Initial injury size

Final injury size

Nyrada Brain Injury Solution

- 📌 Treatment for secondary brain injury following Stroke or TBI
 - Prevent cell death
 - Attenuate damaged brain volume
 - Improve survivability, limit disability, improve quality of life



Walter Reed & UNSW Collaboration

Nyrada
inc

- Collaboration secured with the world-leading scientific teams at Walter Reed Army Institute of Research and UNSW Sydney
- Efficacy and mechanism of action studies to be conducted on Nyrada's preclinical neuroprotection compound
- Aligns with Walter Reed's mission to develop ground-breaking solutions to mitigate the impacts of traumatic brain injury which occurs in 1 in 25 military service members

WRAIR
Walter Reed Army
Institute of Research
Soldier Health • World Health



Signals industry interest in Nyrada's technology

Program Status & Recent Achievements

Proof-of-concept
established





Lead optimisation well
advanced



First-in-human studies
(Phase I)

- Cholesterol-lowering Drug:
late-CY 2021
- Brain Injury Drug:
mid-CY 2022



-  Results from an *in vivo* cholesterol efficacy study showed a **57% reduction** in total cholesterol (announced on 21 December 2020)
-  Nyrada NYX-1010 showed excellent potency and blood-brain barrier penetration

Board of Directors



Mr John Moore
Non-Executive
Chairman



Dr Ian Dixon
Non-Executive
Director



Christopher Cox
Non-Executive
Director





Mr Peter Marks
Non-Executive
Director



**Mr Marcus
Frampton**
Non-Executive
Director



**Dr Rüdiger
Weseloh**
Non-Executive
Director

-  Nyrada operates under the direction of a board of international calibre
-  Track record in founding and realising the value of biotech companies

Key Metrics & News Flow

Market capitalisation
(as at 22 February 2021) **\$39M**

Share price
(as at 22 February 2021) **\$0.355**

CDIs free float **77,719,770**

CDIs 24 months escrow **33,105,853**

Cash at bank (31 Dec 2020) **A\$4.1m**

ASX listing **January 16, 2020**

CY 2021

CY 2022

Cholesterol-lowering program
to enter clinic: ▲

Neuroprotection program
to enter clinic: ▲



Further preclinical results: **ongoing**

Non-dilutive funding: **ongoing**

Discover More & Follow Us

Nyrada
inc



Neuroprotection Animation



Cholesterol-Lowering Animation

info@nyrada.com
www.nyrada.com



[@nyrada_inc](https://twitter.com/nyrada_inc)



[@nyrada_inc](https://www.linkedin.com/company/nyrada_inc)



ASX: NYR